Yapan Bio is a biotech contract development and manufacturing (CDMO) startup based in Hyderabad, India, that provides process development and GMP manufacturing of vaccines and biologics for biopharma partners.

This Startup Deep Dive explains what Yapan Bio does, how it makes money, who backs it, how it compares with rivals and what could go wrong, using publicly available information. It is educational and not investment advice. Last updated: October 2026.

Yapan Bio in Brief

• What it is: Yapan Bio is an Indian Biologics CDMO company based in Hyderabad.
• Who it serves: patients, doctors, hospitals, diagnostic centres, insurers and employers.
• Yapan Bio provides process development and GMP manufacturing for vaccines and biologics, including viral vector vaccines, gene therapies and monoclonal antibodies.
• It supports end-to-end development and manufacturing of RNA, DNA and gene therapy products starting from plasmids.
• Piramal Pharma Solutions markets Yapan's services.
• Funding: Not disclosed in public sources reviewed.

Yapan Bio Quick Facts

Figures marked “reported” come from published reports and may differ between sources; “Not disclosed” means no reliable public figure was found.

What Is Yapan Bio?

Yapan Bio operates in the Biologics CDMO space in India. Understanding a company like this starts with three questions: who is the customer, what painful problem is being solved, and why the solution is better than the alternatives. The sections below apply that lens to Yapan Bio.

• Yapan Bio provides process development and GMP manufacturing for vaccines and biologics, including viral vector vaccines, gene therapies and monoclonal antibodies.
• It supports end-to-end development and manufacturing of RNA, DNA and gene therapy products starting from plasmids.
• Piramal Pharma Solutions markets Yapan's services.

The Origin Story of Yapan Bio

Every company starts from a noticed gap and a team willing to commit to closing it. Strong origin stories are specific: a clear problem, a founding team with relevant skills, and an early product that real customers could test. Founder-market fit, meaning the team’s lived experience or technical depth in the domain, tends to predict how fast a young company learns.

• Founders: Atin Tomar, Nirav Desai.
• Reportedly founded in 2019 by Atin Tomar and Nirav Desai and based at Genome Valley, Hyderabad.
• Sources disagree on its description: one startup database profile calls it a health tech company focused on clinical onco-nutrition, which conflicts with the CDMO descriptions elsewhere.

Key Milestones and Challenges

No startup grows in a straight line. Early years usually involve slow adoption, product rewrites, hiring mistakes and funding gaps. In the Biologics CDMO sector the common turning points are a first paying customer, a regulatory approval, a successful product demonstration or a funding round that lets the team invest ahead of demand. How a team responds to setbacks says more about resilience than any single headline.

• 2019: Founded, per a startup database profile.
• December 2021: Piramal Pharma made its initial strategic minority investment.
• October 2022: Opened a new process development facility.
• Later reports describe Yapan becoming a Piramal subsidiary following an acquisition.

Yapan Bio Funding and Investors

Funding history shows how much outside confidence a company has attracted and how long it can operate before needing more capital. Figures below are reported and may differ between sources; valuation figures are estimates unless the company has confirmed them.

• Detailed round-by-round funding for Yapan Bio is not disclosed in the public sources reviewed.
• Readers should check regulatory filings and company announcements for the latest position.

How Does Yapan Bio Make Money? (Business Model)

A business model describes who pays, how often and how much it costs to serve them. Strong models show repeat usage, improving margins with scale and acquisition channels that do not depend only on paid spend. Weak models show one-off sales, rising costs and growth that stops when spending stops. For companies selling to patients, doctors, hospitals, diagnostic centres, insurers and employers, sales cycles and contract size matter as much as headline growth.

• CDMO model: fee-based development and manufacturing services for biologics clients, marketed through Piramal Pharma Solutions.

The Numbers: Yapan Bio Financials

Financial figures show whether growth is turning into a self-sustaining business. Small and private companies often disclose little, so any number below is included only if it was found in public reporting.

• Reported revenue of Rs 55.8 Cr in FY25, up 87.4% from Rs 29.8 Cr in FY24.

Market Opportunity for Yapan Bio

Market size is easy to exaggerate, so a useful approach separates the total market from the portion a company can realistically reach with its current product and distribution. The main forces behind demand in this sector are rising chronic disease, growing health insurance penetration, government programmes such as Ayushman Bharat and the Ayushman Bharat Digital Mission, and the shift of care to digital and home settings. Each of these widens the opportunity, but capital efficiency and execution decide who captures it.

• Serves the biologics, vaccine and gene therapy outsourcing market.

Technology and Product at Yapan Bio

Technology is rarely the whole moat, but it drives speed, cost and customer experience. A practical way to assess it is to separate the capability the company controls from the commodity infrastructure it rents. In this sector the important factors are clinical validity, data quality, integration with hospital and lab systems, and trust among doctors and patients.

• Capabilities span viral vector vaccines, monoclonal antibodies, and RNA, DNA and gene therapy products from plasmids.

Team and Culture at Yapan Bio

Teams are the most important and least measurable asset of a young company. Look at how complementary the founders’ skills are, how deep the second layer of leadership is, and how the company hires and retains specialists. Culture shows up in small repeated behaviours: how quickly bad news travels upward and whether commitments to customers are kept.

• Reports differ on headcount: about 40 and 55 in different profiles.

Yapan Bio Competitors: Competitive Landscape

A fair competitive analysis names direct rivals, adjacent players who could move into the space, and the customer’s default alternative. Durable advantages include proprietary data or technology, licences and approvals, brand trust, switching costs and cost leadership.

• Direct competitors of Yapan Bio vary by product line; a verified rival comparison was not available from public sources.
• What to compare: Product readiness, pricing, customer base, funding runway and regulatory standing.

Risks and Challenges for Yapan Bio

• Reliance on Piramal as strategic shareholder and sales channel.
• Regulatory risk: medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules.
• Clinical and liability risk: errors in care, diagnosis or product quality can damage trust quickly.
• Data privacy risk: health records are sensitive, and breaches or misuse can bring legal and reputational harm.
• Thin margins: low-ticket services and heavy customer-acquisition spend can keep unit economics weak.

Risk is not a reason to avoid a company; it is a reason to price it correctly and to monitor the right indicators over time. Regulation in this sector is shaped by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Yapan Bio Growth Outlook: What to Watch

• Expanded capacity and capabilities in large-molecule therapeutics with the new process development facility.
• Key indicators: patient or user volumes, repeat usage, gross margin, clinical outcomes and cost of acquiring each customer.
• Funding position: Whether Yapan Bio can reach its next milestone before needing new capital.
• Regulation: Changes from the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Industry Context: Where Yapan Bio Fits

India's healthcare market combines a large public system, a fast-growing private hospital sector and an increasingly digital layer. Government initiatives such as Ayushman Bharat and the Ayushman Bharat Digital Mission aim to widen insurance cover and create common digital health records, while telemedicine guidelines and the Digital Personal Data Protection Act shape how digital care and patient data can be used.

Demand is driven by chronic and lifestyle disease, an ageing population, rising insurance penetration and consumers who now expect to book, pay and consult online. Startups in this field compete on trust, clinical quality and convenience, and they must prove outcomes and safety as well as growth.

For readers new to this field, a useful habit is to separate announcements from evidence. A plan, a partnership or a funding headline describes intent, while a delivered product, a paying customer or an audited financial statement describes results. Comparing the two over time shows how reliably a company turns promises into outcomes.

Bull Case and Bear Case for Yapan Bio

An investment thesis is a short, testable statement of why a company could become far more valuable, together with what evidence would prove it wrong. The points below are general to this sector and are not forecasts for Yapan Bio.

Bull case

• Rising insurance cover and digital adoption expand the customer base.
• Strong clinical evidence builds trust with doctors and hospitals.
• Scale can improve unit economics in diagnostics and care delivery.

Bear case

• Regulatory changes can alter permitted products or business models.
• Customer acquisition costs can erode margins.
• A single safety or privacy incident can damage trust.

Lessons Founders and Investors Can Take from Yapan Bio

Studying a company in the Biologics CDMO space offers lessons that go beyond any single firm. The points below are general lessons for the sector and are not claims about Yapan Bio.

• Trust is the real currency in healthcare, so quality control, clinical evidence and data protection must be built in from the start.
• Distribution through hospitals, clinics, insurers or employers can matter more than a standalone consumer app.
• Unit economics improve when repeat usage replaces expensive one-time customer acquisition.
• Regulatory approvals can take time, so timelines and cash planning should allow for them.
• Integration with existing hospital, lab and records systems reduces friction for adoption.

How to Evaluate Yapan Bio as a Startup

• Customer clarity: Can Yapan Bio name its customer and the problem it solves in one sentence?
• Evidence of demand: Look for repeat customers, signed contracts or measurable usage rather than announcements alone.
• Economics: Check whether margins improve as volume grows.
• Execution: Compare announced timelines with what has actually been delivered.
• Funding runway: Estimate how long current capital lasts at the present spending rate.
• Regulatory standing: Confirm required approvals are in place.
• Customer concentration: Check whether a few customers account for most of the revenue.
• Management depth: Look for experienced leaders beyond the founders and a stable core team.

The Takeaway

Yapan Bio is part of India’s growing Biologics CDMO ecosystem. The useful lesson from studying it is the discipline of asking structured questions about customers, economics, advantage and resilience. Companies that answer them well, repeatedly and under pressure are the ones that endure. Readers should treat any single report, ranking or funding headline as one input among many, and should re-check key facts against recent company announcements. Because public information on young companies is often limited, patience in verifying claims is part of good analysis. This article is educational and is not investment advice.

• Clear customers and repeat demand matter more than announcements.
• Regulation and capital needs shape how fast a startup in this sector can grow.
• Track a few leading indicators over time rather than one headline metric.

Yapan Bio FAQs: Frequently Asked Questions

What is Yapan Bio?

Yapan Bio is a biotech contract development and manufacturing (CDMO) startup based in Hyderabad, India, that provides process development and GMP manufacturing of vaccines and biologics for biopharma partners. It is profiled in the Startup Deep Dive series, which explains business model, funding, competitors and risks.

Who founded Yapan Bio?

Yapan Bio was founded by Atin Tomar, Nirav Desai, and the company reports a founding year of 2019.

How much funding has Yapan Bio raised?

No reliable total funding figure is disclosed in the public sources reviewed. Funding figures are reported and may differ between sources, so readers should check the latest company announcements.

How does Yapan Bio make money?

Yapan Bio earns revenue from its Biologics CDMO products and services sold to patients, doctors, hospitals, diagnostic centres, insurers and employers. The exact revenue mix is described in the business model section and is not fully disclosed publicly.

Who are the competitors of Yapan Bio?

Competitors of Yapan Bio depend on the specific product line. A verified comparison was not available, so see the evaluation checklist above.

What are the main risks for Yapan Bio?

Main risks include medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules, funding and capital needs, competition and regulation by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act. This is educational content, not investment advice.

Related Startup Deep Dives: Cloudnine — Cloudnine: maternity chain with Rs 1,486 Cr FY25 revenue | Strand Life Sciences — Strand Life Sciences: Reliance bought control for Rs 393 Cr. Browse the full Startup Deep Dive series.

Source

Source: Publicly available data, published reports, industry research, and other credible sources.